LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration Small Mol Conc Unit LJP Library Plate Replicate Assay Well Timepoint Timepoint Unit Total Cell Count Before Treatment Total Cell Count After Treatment Total Control Cell Count Relative Cell Count Relative Growth Rate After Treatment
MDA-MB-231 Radicicol
10.0
uM
LJP6
 1
K07
 72
hr
 868 1022 3486 0.2931 0.0588
MDA-MB-231 Radicicol
10.0
uM
LJP6
 2
K07
 72
hr
 868 1107 3486 0.3175 0.0912
MDA-MB-231 Radicicol
10.0
uM
LJP6
 3
K07
 72
hr
 868 1069 3486 0.3066 0.0767
MDA-MB-231 Seliciclib
10.0
uM
LJP5
 1
J01
 72
hr
 868 1604 3486 0.4601 0.2811
MDA-MB-231 Seliciclib
10.0
uM
LJP5
 2
J01
 72
hr
 868 1457 3486 0.4179 0.2249
MDA-MB-231 Seliciclib
10.0
uM
LJP5
 3
J01
 72
hr
 868 1461 3486 0.4191 0.2264
MDA-MB-231 Ruxolitinib
10.0
uM
LJP5
 1
O13
 72
hr
 868 2509 3486 0.7197 0.6267
MDA-MB-231 Ruxolitinib
10.0
uM
LJP5
 2
O13
 72
hr
 868 2921 3486 0.8378 0.7841
MDA-MB-231 Ruxolitinib
10.0
uM
LJP5
 3
O13
 72
hr
 868 2852 3486 0.8180 0.7577
MDA-MB-231 XL147
10.0
uM
LJP5
 1
G07
 72
hr
 868 3387 3486 0.9715 0.9620
MDA-MB-231 XL147
10.0
uM
LJP5
 2
G07
 72
hr
 868 3341 3486 0.9583 0.9445
MDA-MB-231 XL147
10.0
uM
LJP5
 3
G07
 72
hr
 868 3222 3486 0.9242 0.8990
MDA-MB-231 Saracatinib
10.0
uM
LJP6
 1
D07
 72
hr
 868 1976 3486 0.5668 0.4231
MDA-MB-231 Saracatinib
10.0
uM
LJP6
 2
D07
 72
hr
 868 1893 3486 0.5430 0.3914
MDA-MB-231 Saracatinib
10.0
uM
LJP6
 3
D07
 72
hr
 868 1818 3486 0.5215 0.3628
MDA-MB-231 Selumetinib
10.0
uM
LJP6
 1
M07
 72
hr
 868 1447 3486 0.4150 0.2211
MDA-MB-231 Selumetinib
10.0
uM
LJP6
 2
M07
 72
hr
 868 1474 3486 0.4228 0.2314
MDA-MB-231 Selumetinib
10.0
uM
LJP6
 3
M07
 72
hr
 868 1480 3486 0.4245 0.2337
MDA-MB-231 Sirolimus
10.0
uM
LJP6
 1
L13
 72
hr
 868 2799 3486 0.8028 0.7375
MDA-MB-231 Sirolimus
10.0
uM
LJP6
 2
L13
 72
hr
 868 3048 3486 0.8743 0.8326
MDA-MB-231 Sirolimus
10.0
uM
LJP6
 3
L13
 72
hr
 868 3144 3486 0.9018 0.8692
MDA-MB-231 Sorafenib
10.0
uM
LJP6
 1
B07
 72
hr
 868 2391 3486 0.6858 0.5816
MDA-MB-231 Sorafenib
10.0
uM
LJP6
 2
B07
 72
hr
 868 2539 3486 0.7283 0.6382
MDA-MB-231 Sorafenib
10.0
uM
LJP6
 3
B07
 72
hr
 868 2414 3486 0.6924 0.5904
MDA-MB-231 SU11274
10.0
uM
LJP5
 1
J07
 72
hr
 868 1213 3486 0.3479 0.1317